Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CORT NASDAQ:NBRV NYSE:PBH NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORTCorcept Therapeutics$56.46-3.2%$41.92$28.66▼$91.00$6.05B0.361.85 million shs529,630 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/APBHPrestige Consumer Healthcare$46.90+2.1%$58.32$42.62▼$89.37$2.22B0.4506,626 shs1.21 million shsPCRXPacira BioSciences$22.84-2.9%$23.44$18.80▼$27.64$899.74M0.32792,454 shs289,637 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORTCorcept Therapeutics+2.14%+14.20%+33.47%+45.86%-17.70%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%PBHPrestige Consumer Healthcare-11.21%-15.68%-18.83%-31.22%-46.46%PCRXPacira BioSciences+2.13%-0.47%-0.93%+8.08%-3.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORTCorcept Therapeutics$56.46-3.2%$41.92$28.66▼$91.00$6.05B0.361.85 million shs529,630 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/APBHPrestige Consumer Healthcare$46.90+2.1%$58.32$42.62▼$89.37$2.22B0.4506,626 shs1.21 million shsPCRXPacira BioSciences$22.84-2.9%$23.44$18.80▼$27.64$899.74M0.32792,454 shs289,637 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORTCorcept Therapeutics+2.14%+14.20%+33.47%+45.86%-17.70%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%PBHPrestige Consumer Healthcare-11.21%-15.68%-18.83%-31.22%-46.46%PCRXPacira BioSciences+2.13%-0.47%-0.93%+8.08%-3.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORTCorcept Therapeutics 2.75Moderate Buy$70.8325.64% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.33Hold$74.7558.47% UpsidePCRXPacira BioSciences 2.29Hold$29.4029.15% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, NBRV, PBH, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/13/2026CORTCorcept Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$44.00 ➝ $72.005/7/2026PBHPrestige Consumer Healthcare OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$77.00 ➝ $65.005/4/2026CORTCorcept Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $75.005/4/2026CORTCorcept Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/1/2026CORTCorcept Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$73.00 ➝ $88.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/21/2026PBHPrestige Consumer Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/7/2026PCRXPacira BioSciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/26/2026CORTCorcept Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORTCorcept Therapeutics$761.41M7.95$0.89 per share63.23$5.94 per share9.49NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00PBHPrestige Consumer Healthcare$1.09B2.05$4.75 per share9.94$37.04 per share1.27PCRXPacira BioSciences$726.41M1.23$3.81 per share5.97$16.62 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORTCorcept Therapeutics$99.65M$0.35161.0632.40N/A6.14%7.40%5.76%7/30/2026 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/APBHPrestige Consumer Healthcare$214.60M$3.7812.079.361.5517.48%11.62%6.17%N/APCRXPacira BioSciences$7.03M$0.12189.788.72N/A0.70%10.24%5.47%N/ALatest PCRX, NBRV, PBH, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2026PBHPrestige Consumer Healthcare$1.39$1.23-$0.16$1.13$291.99 million$281.62 million4/30/2026Q1 2026CORTCorcept Therapeutics-$0.1085-$0.30-$0.1915-$0.30$185.83 million$164.90 million4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million2/26/2026Q4 2025PCRXPacira BioSciences$0.85$0.57-$0.28$0.04$201.93 million$196.87 million2/24/2026Q4 2025CORTCorcept Therapeutics$0.33$0.20-$0.13$0.20$254.94 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCORTCorcept TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORTCorcept TherapeuticsN/A2.862.77NBRVNabriva Therapeutics0.120.850.52PBHPrestige Consumer Healthcare0.583.111.93PCRXPacira BioSciences0.564.733.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORTCorcept Therapeutics93.61%NBRVNabriva Therapeutics0.27%PBHPrestige Consumer Healthcare99.95%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipCORTCorcept Therapeutics20.70%NBRVNabriva Therapeutics1.63%PBHPrestige Consumer Healthcare1.40%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORTCorcept Therapeutics300107.35 million85.13 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionablePBHPrestige Consumer Healthcare54047.32 million46.66 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionablePCRX, NBRV, PBH, and CORT HeadlinesRecent News About These CompaniesUBS Group AG Has $14.46 Million Position in Pacira BioSciences, Inc. $PCRXMay 14 at 6:56 AM | marketbeat.comDOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR ...May 13 at 5:07 PM | finance.yahoo.comPacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings SuggestMay 13 at 5:07 PM | finance.yahoo.comDOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board CandidatesMay 13 at 10:58 AM | prnewswire.comPacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare ConferencesMay 13 at 8:00 AM | globenewswire.comVanguard Group Inc. Sells 384,612 Shares of Pacira BioSciences, Inc. $PCRXMay 13 at 7:07 AM | marketbeat.comPacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board NomineesMay 12 at 4:01 PM | globenewswire.comHC Wainwright Expects Lower Earnings for Pacira BioSciencesMay 11, 2026 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from AnalystsMay 9, 2026 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comPacira BioSciences Mails Letter to StockholdersMay 5, 2026 | globenewswire.comComparing Pacira BioSciences (NASDAQ:PCRX) & Hoth Therapeutics (NASDAQ:HOTH)May 5, 2026 | americanbankingnews.comAssessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World DataMay 3, 2026 | uk.finance.yahoo.comUniversal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRXMay 2, 2026 | marketbeat.comPharmaCorp Completes Acquisition of Pharmacy Files in Western CanadaMay 1, 2026 | globenewswire.comRoyal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock PriceMay 1, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst UpgradeMay 1, 2026 | marketbeat.comNeedham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00May 1, 2026 | marketbeat.comPacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...May 1, 2026 | finance.yahoo.comPacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestonesMay 1, 2026 | seekingalpha.comPacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, NBRV, PBH, and CORT Company DescriptionsCorcept Therapeutics NASDAQ:CORT$56.46 -1.84 (-3.15%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Prestige Consumer Healthcare NYSE:PBH$46.90 +0.97 (+2.11%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Pacira BioSciences NASDAQ:PCRX$22.84 -0.69 (-2.95%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
